Hjem » GSK joins IMPRESS-Norway

GSK joins IMPRESS-Norway

IMPRESS-Norway has been open for inclusion for over two years and so far more than 1000 patients have had their tumor sequenced through InPreD and over 200 patients have been offered a new treatment. The study is dynamic in the way that new companies and new drugs can be added to the study all the time. It is therefore very nice to welcome GSK to IMPRESS. GSK enters IMPRESS-Norway with an immunotherapy drug and a PARP inhibitor. Together, this agreement provides new treatment options for 48 patients through IMPRESS.

We are very pleased with this! Several patients who are included to IMPRESS have changes in their tumors which indicates that they will have effect from treatment with an immunotherapy or PARP inhibitors. Dr. Katarina Puco, Study doctor in IMPRESS-Norway

European collaborations

IMPRESS-Norway is part of a network of precision cancer medicine trials in Europe. This network of precision medicine studies in Europe has formalized the collaboration through the EU project PRIME-ROSE. This means that we will not only learn more about the treatment effect of GSK’s drugs from IMPRESS-Norway, but from several other studies.

There are many rare forms of cancer that are included in IMPRESS. Fortunately, many of these patients have changes in their cancer which indicate that they may have an effect from drugs that are only approved for one or more of the more common forms of cancer. Through IMPRESS, we get the opportunity to test the treatment effect on these rare cancers, but since they are rare, it is extra important to collect data on treatment effect from many countries. We are therefore pleased that GSK is supporting several of the precision medicine initiatives in Europe. Professor Åslaug Helland, National PI for IMPRESS-Norway

GSK is very happy to contribute to more patients gaining access to trial treatment through the national trial- IMPRESS. Strengthening of the collaboration around clinical studies and research in Norway is an important focus for GSK locally and this is a contribution to achieve this goal. Hege Edvardsen, Acting Medical Director GSK